Published Work

Ixekizumab in the treatment of moderate-to-severe psoriasis: Patient Adherence, Preferences and Satisfaction Summary

2021-07-20T20:13:39+00:00

Ixekizumab (Taltz or IXE) is one of the newer anti-IL-17 antibodies available to patient as an injectable biologic medication. We looked into patient’s adherence, preferences and satisfaction in those treated with this medication.....

Ixekizumab in the treatment of moderate-to-severe psoriasis: Patient Adherence, Preferences and Satisfaction Summary2021-07-20T20:13:39+00:00